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To assess changes in AKT pathway signaling, a recombinant protein of the G3 
domain of rat laminin-5 (rG3) that specifically binds the alpha subunit of integrins α6β1 
and α6β4 expressed on cancer cells (e.g., MDA-MB-231) was produced. This 
recombinant protein is believed to interrupt the intracellular signaling events of the AKT 
pathway, causing a decrease in proliferation and survival of cells after treatment. 
Viability assays confirmed an apoptotic effect of rG3 on cells in a dose-dependent 
manner. However, data from gene expression studies of Caspase-9, GRB10, and 
CDKNIB proved non-conclusive that rG3 is acting upon gene expression, leading to the 
further investigation of the AKT pathway and proteins involved in this signaling cascade. 
P53 and phosphorylation of AKT, NFkB/p65, and IKKαβ were evaluated after treatment 
with rG3 at 0, 3, 6, 9 and 12 hours. Results show significant differences in protein 
expression for these proteins in cells treated with rG3 compared to untreated cells. 
Significantly higher levels of AKT and phosphorylated AKT were seen in untreated cells, 
indicating the inhibitory effect the rG3 protein has on this pathway. Both IKKαβ and the 
phosphorylated IKKβ catalytic subunit were expressed at a significantly higher level in 
untreated cells, as were the levels of phosphorylated nuclear NFκB. These results also 
indicate an inhibition of downstream proteins of the AKT cell survival pathway with rG3 
treatment. Cytosolic NFκB, however, was expressed at significantly higher level in cells 
treated with rG3 when compared with untreated cells because the majority of this protein 
in actively proliferating untreated cells is in the phosphorylated form. The greatest 
change was seen in expression of the pro-apoptotic protein, p53. In treated cells, this 
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protein was expressed at higher levels than in the untreated cells, especially at 9 hours 
after treatment, indicating the large impact rG3 treatment has on the AKT pathway and 
its ability to significantly reduce cell viability through specific signaling events.  
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The mammary gland is an organ of specific tissue organization that depends on 
cell-cell adhesion, interactions with the extracellular matrix, and interactions with the 
intracellular scaffolding of the cell. An important part of the tissue is the basement 
membrane, which is a sheet-like extracellular matrix that covers the basal portion of the 
tissue and provides mechanical stability, barriers between different cell types, and 
contributes to cell differentiation, survival, and migration (Sasaki et al., 2004). Various 
proteins of this basement membrane promote cell adhesion and migration, including 
laminins.  Laminins interact with specific integrin receptors on the cell surface to regulate 
various functions of the cell, including tumor invasion. Integrins are heterodimeric 
transmembrane receptors found at focal adhesions and serve to link the extracellular 
matrix intracellularly as well as with signaling enzymes that direct the survival, growth, 
and migration of cells.  Integrins, laminins, and the basement membrane are important 
elements involved in cancer cell invasion.  Invasion is known as the penetration of tumor 
cells into adjacent tissues, which is a characteristic of malignant tumors (Mercurio and 
Rabinovitz, 2001). By exploiting the functions of integrins, laminins, and intracellular 
signaling cascade proteins, cancer cells can invade and proliferate in the mammary tissue. 
The PI3K/AKT signaling pathway is activated via the integrin-laminin association, and in 
cancer cells, abnormal activity of this pathway is observed.
Laminins
Laminins are trimeric proteins found primarily in the basal lamina. Each laminin 
molecule forms the common cruciform structure with three chains, α, β, and γ, linked by 
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disulfide bonds.  Five α, three β, and three γ chains have been identified (Kariya et al., 
2003).  Various combinations of these chains have yield at least fifteen different known 
isoforms of laminin. The chains intersect to form a structure that can bind to other 
molecules, with the shorter chains binding to other laminin molecules to form sheets and 
the longer chains binding to cells and providing an anchor to the membrane. All laminin 
α-chains contain a globular region at their carboxyl-terminal region that consists of five 
sub-domains (G1-5), while the β and γ chains have globular domains at the amino 
terminal regions of the chain. One specific laminin isoform, laminin-5, has unique 
properties from the other isoforms (Kariya et al., 2003).  It consists of α3Aβ3γ2 chains 
and has been found to promote adhesion, migration, and scattering of cells in culture 
more vigorously than laminin-1, laminin-2, laminin-4, vitronectin, and fibronectin 
(Miyazaki et al., 1993). Laminin-5 regulates the adhesion of the epithelium to the 
underlying connective tissue and keeps it stable by interacting with the integrin cell 
surface receptors. It also differs from other laminin forms in its subcellular localization 
and its cellular receptors. It is a large component of anchoring filaments and plays a 
major role is assembly of the basement membrane (Kunneken et al., 2003). Within the 
five sub-domains of the C-terminal of this laminin, the G3 domain has been proven to be 
essential for the unique biological activity of laminin-5 (Kim et al., 2001). Deletion of the 
G3 domain in recombinant forms of laminin-5 leads to a drastic loss of cell adhesion and 
motility, proving that this domain has an indispensible function in the activity of this 
laminin (Hirosaki et al, 2000). Small changes in the structure of the G3 domain also 
modulate the intracellular signals induced by laminin-5, suggesting that the signaling of 
laminin-5 specifically relies on the G3 domain (Kariya et al., 2003).  Previous studies 
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have shown the G3 domain to contain at least two sites that regulate cell adhesion and 
motility in different ways, and activities of laminin-5 are largely dependent on these two 
sites (Kariya et al., 2003).  Laminin-5 has been found localized in the epithelial-stromal 
interface of many invasive tumors, suggesting that this protein serves as a ligand for 
migratory carcinoma cells. In malignant transformation, the integrity of types of collagen 
and laminin-5 is often lost (Lohi, 2001).  The integrins α6β1, α6β4, and α3β1 are known 
receptors for laminin-5, and have been found on invasive carcinoma cell membranes 
(Lohi, 2001).    
Integrins
Adhesion to the extracellular matrix is also mediated by integrins, a class of 
heterodimeric transmembrane receptors that control many properties of the cell, including 
adhesion, migration, and cell-cycle progression through their signaling capabilities 
(Schatzmann et al., 2003). Integrin heterodimers consist of α and β subunits that are 
noncovalently linked. The subunits can form a minimum of 23 different heterodimeric 
receptors with the majority serving as receptors for proteins of the extracellular matrix 
(Nuzhat et al., 2005). The composition of each heterodimer determines specificity to an 
individual ligand. Integrins and laminins form a network of cell signaling molecules that 
allow the cell to respond to changes in its external environment or within the cell by 
increasing or decreasing the integrin affinity for the ligand (Nuzhat et al., 2005). Integrins 
interact with the extracellular matrix in clusters known as focal adhesions. Two enzymes 
that associate with the focal adhesions of integrins are focal adhesion kinase (FAK) and 
integrin-linked kinase (ILK). These enzymes are essential to modulate cell and 
extracellular matrix interactions by associating with other proteins in cell signaling 
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pathways (Nuzhat et al., 2005). Integrins have been linked to metastasis in numerous 
studies, some specifically linking the α6 subunit in human breast cancer cells with 
tumorigenicity (Mercurio and Rabinovitz, 2001). Integrins also promote survival of the 
cell via activation of phosphatidylinositol 3-kinase (PI3K), integrin-linked kinase (ILK), 
extracellular regulated kinase (Erk), and c-Jun N-terminal kinase (JNK). The PI3K/AKT 
pathway was considered in this research.  
The link between integrins, laminins, and invasion is observed in the three steps 
of the invasion process. Tumor cells must attach to the basement membrane, degrade the 
membrane, and migrate into the stroma (Mercurio and Rabinovitz, 2001).  Integrins are 
essential for invasion due to their association with the extracellular matrix as well as their 
control over signaling pathways in the cell that influence proliferation and growth. As 
mentioned, the α6β4 integrin is a known receptor for laminin-5 and has been linked to 
invasion of tumors and promotion of carcinoma migration (Mercurio and Rabinovitz, 
2001). The feature of the α6β4 integrin that increases its ability to perform these activities 
is the distinctness in the cytoplasmic domain of the β4 subunit. It is 1000 amino acids in 
size and is also different in structure from any other integrin subunit (Mercurio and 
Rabinovitz, 2001). Studies have proved a mechanistic involvement of this subunit in 
activation of PI3K/AKT in invasive cancer cells.
PI3K/AKT Signaling and Apoptosis
The link between α6β4 integrin based progression of breast carcinoma invasion 
and cell signal transduction is the PI3K/AKT cell signaling pathway (Osaki et al., 2004). 
This integrin can activate phosphatidylinositol-3-kinase (PI3K), which is essential for the 
translocation of Akt to the plasma membrane where it is phosphorylated. Phosphorylated 
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AKT then phosphorylates a range of proteins that are fundamental in cell growth and 
survival as well as in some cases, apoptosis (Osaki et al., 2004). In cancer cells, the α6β4 
integrin stimulates the PI3K pathway to a greater level than other integrins (Osaki et al., 
2004). Figure 1 shows the PI3K/AKT pathway and its activation by integrin and laminin.
Figure 1. Activation of Akt Pathway (Turner et al., 2008)
PI3K is a lipid kinase signal transduction enzyme that is involved in cellular 
functions such as growth, differentiation, proliferation, apoptosis, motility, and survival, 
all of which play important roles in cancer. It is a heterodimeric molecule composed of 
regulatory and catalytic subunits. PI3K can be dephosphorylated by the phosphatase and 
tensin homolog (PTEN) tumor suppressor protein, which serves as a negative regulator of 
the PI3K pathway (Vivanco and Sawyers, 2002). The PI3K group has the ability to 





































second messenger phosphatidylinositol-3,4,5-triphosphate (PI-3,4,5-P3). This second 
messenger interacts with Akt (also known as protein kinase B, or PKB), a 
serine/threonine kinase, and serves to translocate it from the cytoplasm to the inner 
membrane, where it is then phosphorylated at two key residues and activated by 
phosphoinositidependent kinase (PDK) 1 and PDK 2 (Osaki et al., 2004). AKT is a 
serine/threonine kinase with an amino-terminal pleckstrin homology (PH) domain, a 
central catalytic domain, and a regulatory domain at the carboxy-terminal. The AKT 
family includes three members, AKT1-3, and each member requires both 
phosphorylation on the Thr308 and Ser472 residues as well as translocation to the plasma 
membrane to be activated. PIP3 on the membrane associates with the PH domain of AKT 
and phosphorylates the molecule (Vivanco and Sawyers, 2002).
 Akt regulates cell cycle progression, survival, and cell migration through 
phosphorylation of downstream proteins including cyclin-dependent kinase inhibitor B 
(CDKN1B)/P27 and pro-apoptotic and apoptotic factors Caspase 9, p53, and BAD 
(Schley et al., 2005).  GRB10 is also suggested as a downstream target in this pathway as 
a co-activator of AKT, helping translocate it to the membrane.  AKT also activates 
NFκB, an important transcription factor for cell growth and survival, through the 
activation of the IκB kinase. IKK will phosphorylate the inhibitor of kappa B protein 
(IκB) that will release NFκB and allow it to localize to the nucleus, where it can induce 
transcription of many genes including anti-apoptotic genes (Merav et al., 2005). 
PI3K first became of interest in the mid 1980’s in the cancer research field when 
its activity was linked to viral oncogene transformation. The regulatory subunit of PI3K, 
p85, associates with many tyrosine kinases through the interaction of its SH2 domain 
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with the kinase phosphotyrosine residues. The regulatory subunits of PI3Ks are encoded 
with α, β, or γ genes, which can be alternatively spliced, whereas the catalytic subunit is 
composed of α, β, or δ genes. After PI3K activation, PIP3 phosphatases are activated. The 
phosphatase that is most obviously involved in oncogenesis is PTEN, and it functions to 
convert PIP3 back to PIP2. It has been proven that the PIP3 phosphatase activity is 
responsible for PTEN and its tumor suppression activities (Vivanco and Sawyers, 2002).
Further downstream, several important molecules are affected by AKT. Apoptosis 
normally controls excessive proliferation via AKT and the phosphorylation of 
components of the apoptotic pathway including BAD and Caspase-9, as well as indirectly 
affecting two other cell death regulators, NFκB (through IKK activation) and the tumor 
suppressor p53. p53 is a pro-apoptotic molecule normally degraded by the p53 binding 
protein, or ubiquitin ligase mouse double minute homolog 2 (MDM2) when it is 
phosphorylated by AKT. AKT is also a survival kinase that regulates the cell cycle by 
preventing degredation of cyclins and allowing them to accumulate (Igor and Sawyers, 
2002).
NFκB is a heterodimer composed of p50 and p65 subunits (Madrid et al., 2000). It 
can activate gene expression and regulate genes that control cell proliferation, survival, 
and transformation with the presence of transactivating domains in the 120 amino acids 
in the C-terminal of the p65 protein, also known as RelA. In normal cells of the 
mammary epithelium, NFκB proteins are located in the cytoplasm where they are 
sequestered with inhibitory IκB proteins until these proteins are phosphorylated and can 
dissociate from NFκB (Romieu-Mourez et al., 2001). The IKK complex is composed of 
three subunits, α, β, and γ. IKKα and IKKβ have a high degree of similarity and are both 
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catalytic subunits, whereas the γ subunit is regulatory. IKKβ, however, mediates most 
phosphorylation of IκB proteins and is responsible for most of the activation of signal 
transduction pathways leading to NFκB activation and has been shown to be involved in 
apoptosis to a greater extent than IKKα (Hacker and Karin, 2006). Once the IKK 
complex is phosphorylated by AKT, IκB proteins of the complex are targeted for 
degredation by the 26S proteasome, a large protein complex that degrades proteins by 
destroying their peptide bonds. NF-κB is then free to regulate transcription in the nucleus. 
Optimal induction of NF-κB target genes involves phosphorylation of certain NF-κB 
proteins, specifically p65 (Viator, et al., 2005). It has also been shown that NF-κB is an 
important mediator in signaling pathways of apoptosis, and also that NF-κB blocks 
apoptosis in several different tissues.  Inactivating this protein makes the cells more 
susceptible to agents that induce apoptosis (Wang et al, 1998). However, it has been 
shown that the induction of p53 can activate NFκB and the two proteins function in 
concert to induce apoptosis. Although NFκB is essential in cell growth and transcription 
of genes for survival, it also is suggested to be essential in p53-mediated apoptosis (Ryan 
et al., 2000). Evidence suggests a pro-apoptotic role for dimers of NFκB, indicating that 
the protein can be an activator or an inhibitor of apoptosis depending on the levels of 
RelA and another subfamily of NFκB, c-Rel (Dolcet et al., 2005). Studies show that 
attenuation of normal NFκB by treatments that inhibit this protein induce apoptosis 
(Mun-Ock et al, 2008). It has been observed that inhibition or loss of NFκB activity can 
repeal p53-mediated apoptosis, indicating that NFκB is both essential in cell growth and 
death (Ryan et al., 2000). In most cases, NFκB is not directly changed, but is held active 
by mutation of upstream components, such as AKT (Grivennikov et al., 2010). 
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p53 is a tumor suppressor protein that is critical in cell cycle regulation and also 
apoptosis when necessary. In unstressed cells, p53 is negatively regulated by the p53-
binding protein MDM2, which blocks the apoptotic properties of p53 and also targets it 
for ubiquitination (Igor and Sawyers, 2002). This is part of a negative feedback loop, 
because MDM2 is also a target of p53 for transcription. MDM2 is phosphorylated by 
AKT and can translocate into the nucleus, enhancing p53 degredation further. 
The interactions between the PI3K/AKT pathway and the p53 apoptosis pathway 
also are present downstream and include the target of p53, cell cycle regulator protein 
p21Cip1/WAF1. This protein is stabilized when the AKT pathway is activated, similar to the 
inhibition seen when AKT phosphorylates the cell cycle inhibitor p27Kip1 (CDKN1B) at 
the threonine 157 site resulting in retention of the protein in the cytoplasm and inhibition 
of this protein that if transcribed can inhibit DNA synthesis (Chang et al., 2003).  p27Kip1 
ensures an orderly progression of the cell cycle, and studies have shown that 
overexpression of this protein in cancer cells results in halting of the cell cycle and 
apoptosis (Katayose et al., 1997). AKT is linked in this way to cell cycle regulation, 
which is important in the progression of cancer (Franke et al., 2003). 
PI3K/AKT and Cancer
Survival, proliferation, and growth are all effects of AKT that can contribute to 
cancer if they are not controlled, and there is a strong link between PI3K/AKT 
deregulation and aberrations in many types of cancer. It has also been shown that the 
α6β4 integrin relies on the PI3K pathway for breast carcinoma survival by associating 
with a receptor on the surface of the cells. The α6β4 integrin is required for PI3K 
activation, invasion, and subsequent AKT signaling to promote the survival of the cells 
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(Mercurio et al., 2001). The stimulation of cell survival through the AKT pathway by 
α6β4 integrins is only apparent in cells with inactive or mutated p53 (Mercurio et al., 
2001). The extensive list of proteins in the AKT pathway contains many in which 
mutations at the DNA level have been reported in tumors (Igor and Sawyers, 2002). 
Samuels et al have reported gene mutations and amplification in the gene encoding the 
P110 catalytic subunit of PI3K in breast cancer, as well as the regulatory subunit of PI3K, 
p85. Amplification in the gene encoding for AKT2 has been reported in breast cancers, as 
well as overexpression in mRNA from AKT3 (Osaki et al., 2004). An over-active AKT 
pathway is seen in vivo for many cancer cell types, including breast and ovarian cancer, 
and linked with poor prognosis (Osaki et al., 2004). Much of the evidence for the 
involvement of the AKT pathway in cancer stems from the involvement of the PTEN 
tumor suppressor gene. Loss of PTEN function has been seen in many cancers and leads 
to the overexpression of AKT and exploitation of this pathway by cancer cells for 
excessive growth (Chang et al., 2003). Downstream protein expression is altered in 
cancer as well. Most of the primary human and rodent breast tumor tissue samples show 
high levels of nuclear NFκB (Romieu-Mourez et al., 2001), and many cancers have been 
found to have a defect in the ability to produce p53 or a mutation in the gene encoding for 
this protein (Ryan et al., 2000). Abnormal signals for growth, proliferation, and apoptosis 
from the Pi3K/AKT pathway have been linked to malignant transformation (Chang et al., 
2003) and make the pathway and apoptosis a target for treatment and study by the 




Recombinant G3 Expression and Purification 
The G3 domain of the rat Laminin-5 α3 chain was generated through polymerase 
chain reaction (PCR) amplification from a plasmid containing a length of the G3 domain. 
The G3 cDNA was cloned into a vector including an ampicillin resistance gene to allow 
for selection of the plasmid and an N-terminal 6X-histidine tag. ArcticExpress™ cells 
were used for expression of recombinant G3 (rG3). Once cells were induced for protein 
expression and harvested, they were prepared for separation by SDS-PAGE to confirm 
rG3 expression. Once soluble rG3 expression was confirmed, a culture was prepared to 
yield a larger volume of the recombinant protein for purification. A protein concentration 
of the product was determined by performing a Bio-Rad Bradford Protein Assay, and the 
fraction was applied to a G50 Sephadex column for size exclusion separation. As 
previously demonstrated, the molecular weight of rG3 including the histidine tag is ~27 
kDa (Turner, 2005). To determine which fractions contained the purified protein, an OD 
reading was taken, and to confirm the identity of the expressed soluble protein as rG3, a 
Western Immunoblot was performed using an anti-polyHistidine monoclonal antibody. 
Cell Culture
MDA-MB-231 cells are a metastatic breast cancer cell line obtained from a 51-
year old female patient, derived from a pleural effusion removed on October 17, 1974. 
This invasive cell line displays an epithelial-like morphology and forms mammary fat 
pad tumors in nude mice.  These cells have lost expression of both estrogen and 
progesterone receptors (Brinkley, BR et al., 1980). MDA-MB-231 human breast cancer 
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cells were grown in 75 cm2 tissue culture flasks and maintained at 37ºC with 5% CO2. 
The cells were maintained in Dulbecco’s Modified Eagles’ Medium (DMEM) with 4.0 
mM L-glutamine and 4500 mg/L glucose (HyClone, Logan, Utah).  The culture medium 
was supplemented with 10% bovine growth serum, penicillin G (100 
units/ml)/streptomycin sulfate (100 µg/ml) and sodium pyruvate (0.11 µg/ml).   Cells 
were routinely passaged using a PBS wash (2X), addition of 400uL cell-stripper 
(Mediatech, Manassas, Virginia) and incubation for 8 minutes at 37ºC in a humidified 
incubator (5% CO2). They were then spun down at 820 rpm for approximately 10 minutes 
and resuspended in fresh culture medium before being allotted to new flasks. A viable 
cell count was performed using trypan blue on a hemacytometer.
Real-Time PCR
To observe changes in gene expression of treated and untreated cells, MDA-MB-
231 cells were plated at 3 x 106 cells/well in a Falcon 6-well tissue culture plate (Falcon, 
Franklin Lanes, NJ) in a 2 ml volume of DMEM (HyClone, Logan, Utah) without 
antibiotic in duplicate. rG3 solution or corresponding control buffer was added to 
treatment wells for a final concentration of 175 µg/ml due to the higher concentration of 
cells needed for this procedure as compared to the MTT assay and following the 
microarray assays completed previously. Treatment and control cells were incubated 
overnight at 37ºC in a humidified incubator (5% CO2). Cells were collected at 0, 12, 24, 
36, 48, and 60 hours after treatment using a PBS wash (2X), addition of 8 ml cell-stripper 
and incubation for 8 minutes at 37ºC in a humidified incubator (5% CO2). The cells were 
then pelleted at 14,000 x g in a bench-top micro-centrifuge for five minutes. Cells were 
suspended in 100μl RNAlater® (Qiagen, Valencia, California) until RNA isolation was 
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performed. RNA was isolated using RNeasy kit (Qiagen, Valencia, California) according 
at manufacturer's instructions. An eppendorf Mastercycler® realplex (Eppendorf, 
Hamburg, Germany) 96-well plate reader was used for PCR analysis. Standard curves 
with housekeeping gene primers were optimized and beta actin was chosen at a 
concentration of 75 ng/ml and a temperature of 56ºC. RNA from each duplicate time 
point was added at a concentration of 10 ng/well on a 96-well, 25 μl twintec-skirted plate 
along with Master Mix containing 2X Buffer, Rt Enhancer, Primers, and Verso Enzyme 
mix from a Verso SYBR 1-step QRT + Rox kit (Thermo Scientific, Waltham, 
Massachusetts). All PCR reactions were performed in triplicate at 56ºC with CDKN1B 
GRB10, and Caspase-9 forward and reverse primer sets (all from Integrated DNA 
Technologies, Coralville, Iowa)  along with the housekeeper (beta actin, Integrated DNA 
Technologies) also in triplicate. Genes of interest were chosen based on preliminary 
changes of expression from a microassay done previously. See Table A1 for primer 
sequences. Fold change was calculated using Pfafl’s Equation as follows:
  Where the numerator is for the gene of interest at a certain time 
point and the denominator is the control with E = efficiency of standard curve.
MTT Viability Assay
To assay for cell viability after varying treatments with rG3, triplicate MTT (3-
[4,5-Dimethylthiozol –2-yl] –2, 5-diphemyltetrazolium bromide) assays were performed 
with purified rG3 and controls, including untreated cells and blank wells with no cells 
present. Cells were collected as previously described and plated at 1 x 104 per well in 100 
µl of antibiotic-free medium and the plate was incubated overnight at 37oC in a 
humidified incubator (5% CO2).  rG3 was diluted in culture medium to concentrations of 
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4, 6, and 8 µg/ml. Cells were either treated with the different concentrations of rG3 or 
with 100 µl of culture medium for a total of 200 µl per well except in background wells 
which contained 100 µl of culture medium only and no cells. The background wells allow 
the plate reader to calculate the normalized the OD of wells containing cells. The treated 
and untreated cells were then incubated for 20 hours at 37oC in a humidified incubator 
(5% CO2).  20 µl of MTT (Sigma-Aldrich Co., St. Louis) was added to all wells and 
incubated for 4 hours.  At the end of the 4 hr incubation, the culture supernatant was 
removed from the wells and 150 µl of dimethylsulfoxide (DMSO) were added to 
solubilize cells.  The plate was shaken for 15 min and absorbance values for the MTT 
reaction were recorded using a BioTek plate reader at dual wavelengths of 570/650 nm. 
Optical Density (OD) values were used to create a stimulation index (SI), which was 
calculated using the ratio of treatment OD ÷ control OD. 
Western Blotting
To determine any effects of rG3 treatment on signaling in cells, proteins of the 
AKT pathway were observed at different time points in MDA-MB-231 cells. The 
proteins of interest were AKT, p53, IKK-beta/alpha, and NFkB (p65), with beta-actin as 
a housekeeping protein. Antibodies used were ordered from Cell Signaling Technology 
(Boston, Massachusetts). The cells were stripped and counted as previously stated and 
plated at 3 x 105 cells/ml in a Falcon 6-well tissue culture plate (Falcon, Franklin Lanes, 
NJ). The cells were allowed to adhere overnight at 37oC in a humidified incubator (5% 
CO2).  The following day, treated cells received 40 µg/ml of rG3, while untreated cells 
received a corresponding volume of medium. This concentration differs from RT-PCR 
concentrations due to the lesser amount of cells used, but all rG3 came from the same 
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stock.  Following a 0, 3, 6, 9, or 12 hr treatment, cells were washed with PBS and lysed 
with 100 µl of 1X SDS sample buffer by incubating 5 minutes on ice. The cells were 
scraped and transferred to a microcentrifuge tube and pelleted with a 10 minute spin in a 
microcentrifuge at 10,000 rpm. To reduce sample viscosity, the cells were vigorously 
pipetted up and down to shear DNA before centrifugation.  The supernatant was removed 
and transferred to a separate microcentrifuge tube and frozen until needed. In preparation 
for protein separation by SDS-PAGE, a sample was boiled for 5 minutes with an equal 
volume of Laemmli Buffer with 2-mercaptoethanol added.  Treated and untreated lysate 
samples at different time points were loaded onto a 10-20% Ready Gel Precast Gel (Bio-
Rad Laboratories, Inc., Hercules, CA) together with a biotinylated protein ladder (Cell 
Signaling Technology, Inc.).  The gel was run in the Ready Gel System (Bio-Rad 
Laboratories, Inc., Hercules, CA) at 200 V for 30 minutes. Meanwhile, a sheet of 
Immuno-Blot™ PVDF Membrane and two pieces of 14 x 11 cm filter pads (Bio-Rad 
Laboratories, Inc., Hercules, CA) were soaked in chilled Western transfer buffer for at 
least 30 minutes.  Following electrophoresis, the gel was washed in cold Western transfer 
buffer for 30 min.  The filter pads, gel, and PVDF membrane were arranged in a layered 
fashion, and protein transfer was completed at 100 V for 45 minutes using a Trans-Blot 
Semi-Dry Transfer Cell.  Non-specific proteins were blocked with a 30 minute 10% 
Blotto incubation at room temperature on a shaker, followed by alternating washes with 
PBS and TBS.  An overnight primary antibody incubation at 4oC was performed with the 
rabbit antibodies phospho-Akt (Ser 473), Akt (pan; C67E7), beta actin (13E5), p53 (7F5), 
phospho-IKK-alpha/beta (Ser176/180), IKK-beta, NFκB (p65), and phospho-NFκB (p65) 
at dilutions according to manufacturer’s instructions (Cell Signaling Technology, Inc.). 
15
Following primary antibody incubation, a 15 min wash with PBS/Tween 20 was 
performed to remove unbound antibody.  Next, a secondary anti-rabbit IgG HRP-linked 
antibody was added for 1 hr at RT.  Protein detection was obtained through the use of the 
HR Peroxidase Visualization Kit (Vector Laboratories, Burlingame, California).
Western Blot Densitometry Analysis
To show quantitative changes in protein expression seen in the Western Blots, the 
relative densities of bands for each protein were calculated using ImageJ software from 
the National Institute of Health (Bethesda, Maryland). Western images (.jpeg) were 
imported into the software and converted to grayscale. Bands were selected manually and 
plotted by their relative densities, with higher peaks representing darker bands. The peaks 
were manually closed off and the area under each peak was measured and converted to a 
percentage density of all peaks for all bands of the image. Then, the percent value was 
divided by the untreated control percent density value to produce a relative density value 
for each band, with a value of 1 for the control, less than 1 for lower expression of the 
protein, and greater than 1 for higher expression of the protein.
Statistical Analysis
Analysis of Variance (ANOVA) was performed on all data collected from 
viability and Western Blot densitometry assays using the Statistical Analysis System 
(SAS, Research Triangle Park, NC).  The general linear model (GLM) procedure was 





Genes of interest were chosen based on a previous microarray that suggested 
potential changes of expression in CDKN1B, GRB10, and Caspase-9 when MDM-MB-
231 cells were treated with rG3. Primers for these genes were used with sequences as 
seen in Table A1 in the Appendix. 
After analyzing several housekeeping genes to use as a control, beta actin was 
chosen because of the high efficiency and R2 seen in the RT-PCR standard curve. This 
gene is often chosen as a control because of its consistent expression in cells. The 
standard curve for beta actin is shown in Figure A2 in the Appendix. 
To observe changes in gene expression of human breast cancer cells following 
rG3 treatment, RNA was isolated from treated and untreated cells and RT-PCR was 
performed in triplicate. Fold change of each gene of interest was calculated based on the 
Ct values by using Pfafl’s formula. There were no significant effects of rG3 on gene 
expression, and all RT-PCR results can be found in the Appendix. Fold changes for 
CDKN1B can be seen in Figure A3.  Three separate RT-PCR trials were performed on 
RNA collected at each time point (0, 12, 24, and 36 hours) after treatment, which can be 
seen on the horizontal axis of Figure A3. There were very small changes in expression 
seen for two of the three trials, and an unusually large increase in expression seen in Trial 
Two at 12 and 36 hours after rG3 treatment. GRB10 and Caspase-9, however, had 
marginal changes in expression after treatment with rG3, none of which rose above a 4-
fold change. These slight changes for GRB10 and Caspase-9 can be seen in Figure A4 
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and Figure A5, respectively. The variation in CDKN1B expression could be due to its 
role as a cyclic gene and varies depending on which cycle stage the cells were in at the 
time. It was surprising that greater trends were not seen in the expression of GRB10 and 
Caspase-9, especially since Caspase-9 is involved in the apoptotic pathway and has been 
observed in previous research (Turner and Borick, 2008) to be affected by rG3 treatment. 
After re-evaluation, it was decided to investigate the trends in expression of signaling 
components of the PI3K/AKT pathway at the protein level rather than the gene levels.
MTT Viability Assay
Since such small changes in gene expression were seen from the RT-PCR data, 
three replicate 24-hour MTT viability assays were performed with 0, 4, 6, and 8 μg/ml 
concentrations of rG3 to confirm that the rG3 was in fact affecting the viability of the 
cells.  As shown in Figure 2, rG3 exhibited an inhibitory effect on the cells.  With a 
treatment level of both 6 and 8 μg/ml, the stimulation indices (SI) of the cells were 
significantly reduced from the control, and reduction can be seen beginning at 
concentrations of 4 μg/ml. The cells show incremental inhibition by treatment with rG3 
after only 24 hours of continuous treatment. 
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Figure 2.  Viability assays were performed with the MDA-MB-231 breast cancer cell 
line with varying concentrations of rG3.  Optical density (OD) of dissolved MTT was 
recorded at dual wavelengths of 570/650 nm.  Stimulation index (SI) is the calculated 
ratio of treatment OD ÷ control OD.  *P ≤ 0.01 for differences between treatments and 
from control. 
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Western Blotting and Densitometry Analysis
Since it could not be confirmed that rG3 was affecting gene expression, but a 
definite decrease in viability due to rG3 treatment of the cells was seen with the MTT 
assays, treated and untreated cells were analyzed by Western Blots to determine how 
signaling components of the PI3K/AKT pathway were affected by the rG3 treatment. The 
pathway proteins chosen were phospho-AKT (Ser 473), AKT (pan; C67E7), beta actin 
control (13E5), p53 (7F5), phospho-IKKαβ (Ser176/180), IKKβ, NFκB (p65), and 
phospho-NFκB (p65).
 All original Western Blot images from which density of bands were analyzed can 
be found in the Appendix. For the beta actin housekeeping protein, in Figure A6, bands 
of a relatively constant intensity can be seen, which is confirmed in the densitometry 
analysis (Figure 3) with a constant relative density around 1 and no differences between 
treated and untreated cells with the exception of a small difference 3 hours after treatment 
and incubation.
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Figure 3.  Beta Actin expression in rG3 treated and untreated MDA-MB-231 breast 
cancer cells. Cells were allowed to adhere overnight at 37oC in a humidified incubator 
and the following day, treated cells received 40 µg of rG3, while untreated cells received 
a corresponding volume of medium. Following a 0, 3, 6, 9, or 12 hr incubation, cells were 
lysed with 100 µl of 1X SDS sample buffer, run on a 10-20% Ready Gel Precast Gel, and 
analyzed with a Western Blot and ImageJ densitometry software. *P ≤ 0.01 for 
differences in treated vs. untreated cells at each corresponding time point.
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In Figures A7 and A8, the band intensity is greater for both AKT and phosphorylated 
AKT, respectively, in untreated cells than cells treated with rG3. The relative density of 
both AKT and phosphorylated AKT is significantly lower in cells treated with rG3 
compared to untreated cells.  In Figures 4 and 5, the relative density of both AKT and 
phosphorylated AKT, respectively, increases with time in the untreated cells. In treated 
cells, the levels of AKT and phosphorylated AKT are lower after 12 hours of treatment 
when compared to 3 hours of treatment.
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Figure 4.  AKT expression in rG3 treated and untreated MDA-MB-231 breast cancer 
cells. Cells were allowed to adhere overnight at 37oC in a humidified incubator and the 
following day, treated cells received 40 µg of rG3, while untreated cells received a 
corresponding volume of medium. Following a 0, 3, 6, 9, or 12 hr incubation, cells were 
lysed with 100 µl of 1X SDS sample buffer, run on a 10-20% Ready Gel Precast Gel, and 
analyzed with a Western Blot and ImageJ densitometry software. *P ≤ 0.01 for 
differences in treated vs. untreated cells at each corresponding time point.
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Figure 5.  AKT expression in rG3 treated and untreated MDA-MB-231 breast cancer 
cells. Cells were allowed to adhere overnight at 37oC in a humidified incubator and the 
following day, treated cells received 40 µg of rG3, while untreated cells received a 
corresponding volume of medium. Following a 0, 3, 6, 9, or 12 hr incubation, cells were 
lysed with 100 µl of 1X SDS sample buffer, run on a 10-20% Ready Gel Precast Gel, and 
analyzed with a Western Blot and ImageJ densitometry software. *P ≤ 0.01 for 
differences in treated vs. untreated cells at each corresponding time point.
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In Figure A9, a discernable difference in band intensity of the p53 tumor suppressor 
protein between treated and untreated cells can be observed. The band intensity increases 
slightly in untreated cells beginning at the 9th hour after treatment, but is darker than the 
control in the treated cells beginning at only 3 hours after rG3 treatment. The intensity 
continues to develop up to 12 hours after treatment, with the most intense density at 9 and 
12 hours. This is confirmed in Figure 6, which shows the relative density of bands as 
significantly greater in treated cells as compared to untreated and the greatest relative 
density of above 5 and above 25 at 9 and 12 hours after treatment, respectively. These 
results indicate that rG3 is affecting the activity of p53 via the PI3K/AKT signaling 
pathway.
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Figure 6.  p53 expression in rG3 treated and untreated MDA-MB-231 breast cancer cells. 
Cells were allowed to adhere overnight at 37oC in a humidified incubator and the 
following day, treated cells received 40 µg of rG3, while untreated cells received a 
corresponding volume of medium. Following a 0, 3, 6, 9, or 12 hr incubation, cells were 
lysed with 100 µl of 1X SDS sample buffer, run on a 10-20% Ready Gel Precast Gel, and 
analyzed with a Western Blot and ImageJ densitometry software. *P ≤ 0.01 for 
differences in treated vs. untreated cells at each corresponding time point.
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In Figure A10, the differences in band intensities are not as easily observed as the 
p53 analysis. Referring to the densitometry quantification in Figure 7, the relative density 
of bands for phosphorylated IKKβ is significantly higher in the untreated cells as 
compared to the treated cells, and is also significantly different between time points, 
showing a gradual increase in expression of phospho-IKKβ while treated cells have very 
low levels. 
Both the Western Blot in Figure A11 and the relative density plot in Figure 8 
show an increase in IKKαβ in the untreated cells. The band intensity, and therefore 
IKKαβ expression, is significantly higher in the untreated cells than the treated cells. The 
relative density of treated cell expression is significantly lower at each increasing time 
point, indicating a time-dependent manner of inhibition from rG3. 
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Figure 7.  phospho-IKKβ expression in rG3 treated and untreated MDA-MB-231 breast 
cancer cells. Cells were allowed to adhere overnight at 37oC in a humidified incubator 
and the following day, treated cells received 40 µg of rG3, while untreated cells received 
a corresponding volume of medium. Following a 0, 3, 6, 9, or 12 hr incubation, cells were 
lysed with 100 µl of 1X SDS sample buffer, run on a 10-20% Ready Gel Precast Gel, and 
analyzed with a Western Blot and ImageJ densitometry software. *P ≤ 0.01 for 
differences in treated vs. untreated cells at each corresponding time point.
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Figure 8. IKKαβ expression in rG3 treated and untreated MDA-MB-231 breast cancer 
cells. Cells were allowed to adhere overnight at 37oC in a humidified incubator and the 
following day, treated cells received 40 µg of rG3, while untreated cells received a 
corresponding volume of medium. Following a 0, 3, 6, 9, or 12 hr incubation, cells were 
lysed with 100 µl of 1X SDS sample buffer, run on a 10-20% Ready Gel Precast Gel, and 
analyzed with a Western Blot and ImageJ densitometry software. *P ≤ 0.01 for 
differences in treated vs. untreated cells at each corresponding time point.
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The Western Blot for NF-κB in Figure A12 shows increasing band intensity in 
untreated cells until 9 hours incubation time without rG3 and decreases slightly at 12 
hours. The trends are confirmed in relative density plots of Figure 9. In treated cells, the 
amount of NFκB is significantly higher than in the control untreated cells. There is also a 
significant peak of expression compared to the other time points in both treated cells and 
untreated cells at 9 hours after treatment.
Figure A13 shows increasing band intensity in untreated cells for phosphorylated 
NFκB (Figure 10) with levels peaking at 6 and 9 hours incubation and decreasing at 12 
hours. In the densitometry analysis, a significantly higher level of expression is seen in 
the untreated cells as compared to treated, with a significant peak at 6 hours after 
treatment.
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Figure 9. NFκB expression in rG3 treated and untreated MDA-MB-231 breast cancer 
cells. Cells were allowed to adhere overnight at 37oC in a humidified incubator and the 
following day, treated cells received 40 µg of rG3, while untreated cells received a 
corresponding volume of medium. Following a 0, 3, 6, 9, or 12 hr incubation, cells were 
lysed with 100 µl of 1X SDS sample buffer, run on a 10-20% Ready Gel Precast Gel, and 
analyzed with a Western Blot and ImageJ densitometry software. *P ≤ 0.01 for 
differences in treated vs. untreated cells at each corresponding time point.
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Figure 10. Phospho-NFκB expression in rG3 treated and untreated MDA-MB-231 breast 
cancer cells. Cells were allowed to adhere overnight at 37oC in a humidified incubator 
and the following day, treated cells received 40 µg of rG3, while untreated cells received 
a corresponding volume of medium. Following a 0, 3, 6, 9, or 12 hr incubation, cells were 
lysed with 100 µl of 1X SDS sample buffer, run on a 10-20% Ready Gel Precast Gel, and 
analyzed with a Western Blot and ImageJ densitometry software. *P ≤ 0.01 for 




One of the most important mechanisms regulating cell growth, survival, and 
apoptosis is the PI3K/AKT pathway mediated by the binding of integrins on the cell 
membrane to Laminin-5 in the ECM. Tumor cells can exploit this pathway by expressing 
certain integrins on their surface, leading to an increase in metastasis. Alterations in and 
overexpression of the PI3K/AKT pathway have been seen in many types of cancer, and 
inhibition of this pathway is implicated in potential cancer thereapy (Osaki et al., 2004).
Specifically, the α6β4 integrin expression increases tumor cell invasiveness, 
especially in breast carcinomas (Aiyer and Varner, 2005). It has been proven that the 
integrin subunits α3 and α6 bind to Laminin-5 G subdomains found at the C-terminal end 
of the α chain to increase metastasis and tumor growth (Hirosaki et al., 2000). In 2003, 
Kariya et al. provided evidence for the major role of the G3 subdomain of Laminin-5 in 
tumor development through a series of deletions and mutations in the human G3 domain. 
Previous research has proved rG3 binding to cancer cells is specific for the α integrin 
subunit, but fails to engage the β subunit necessary for signaling through cell survival 
pathways. It is also shown that the ligand binding specificity leads to reduced cell 
viability through pro-apoptotic signaling events (Turner, 2008). 
 To determine specifically which signaling events, proteins, and genes are 
involved in the altered survival pathway due to rG3 treatment, the breast cancer cell line 
MDA-MB-231 was selected for observation based on its high expression of α6β4 
integrins. The recombinant G3 protein previously engineered (Turner, 2008) was used to 
assay signaling activity at both a genetic and protein level following treatment with 
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varying levels of rG3. Figure 11 shows hypothesized altered events of the cell survival 
signaling pathway with rG3 treatment (Turner, 2008). In theory, in treated cells, AKT, 
IKKαβ, GRB10, and NFκB, expression should go down, while p53, Caspase-9, and 
CDKN1B expression should increase.
Figure 11. Inactivation of the Akt pathway following binding of rG3 to the alpha 
component of the integrin heterodimer leading to induction of apoptosis.
The genes GRB10, CDKN1B, and Caspase-9 were chosen for investigation using 
Real-Time PCR based on previous microarray data and their known involvement in cell 
survival and apoptotic pathways. The GRB10 gene encodes growth factor receptor bound 
protein 10 in humans, and has been suggested as a downstream target in the PI3K 
pathway. No direct effect of this protein has been observed on PI3K or AKT, but there is 
evidence that the expression level of GRB10 may influence AKT activity (Jahn et al., 


























it is overexpressed and that a complex is formed between GRB10 and AKT. This 
suggests that it is an adaptor protein that aids to relocalize AKT to the cell membrane, 
therefore acting as a positive regulator of the AKT pathway (Jahn et al., 2002). These 
findings suggest that when the cell undergoes apoptosis due to rG3 treatment, decreased 
expression of GRB10 will be observed because the cell is no longer using the AKT 
pathway for cell proliferation and growth, reducing the amount of AKT that is 
translocated to the membrane in a complex with GRB10. 
The CDKN1B gene encodes the p27Kip1 protein that is involved in regulating 
cyclins, or proteins forming complexes that guide cell cycle progression through multiple 
stages. It has been suggested that in cell surivival, AKT stimulates cell cycle progression 
by activating this cyclin dependent kinase inhibitor and causing it to be retained in the 
cytoplasm where it cannot produce growth-inhibitory effects (Chang et al., 2003).
Caspase-9 is a crucial mediator of apoptosis and is directly involved in the 
apoptotic signaling pathway. It is an initiator Caspase and its activation results in a 
cascade of additional Caspase activation eventually resulting in apoptosis (Salveson, 
1998). Based on these conclusions, it would be expected that when MDM-MB-231 breast 
cancer cells are treated with rG3 and undergo apoptosis, gene expression of Caspase-9 
would be upregulated, while GRB10 and CDKN1B gene expression would be down-
regulated. 
RT-PCR results show large inconsistency between the three trials and do not 
show a large enough fold change of gene expression for GRB10, CDKN1B, or Caspase-9 
to conclude that rG3 is altering their expression. In trial 1, CDKN1B shows major 
upregulation, but this result could not be repeated in the other two trials. This is possibly 
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due to the fact that it is a cyclic regulator and its expression depends on what cell cycle 
stage the cells are in, which was not controlled for in this experiment. Caspase-9 was 
expected to have a much larger fold change due to the fact that it is a direct activator of 
the apoptotic pathway, and GRB10 showed very small changes in expression as well as 
inconsistency of expression when treated with rG3. Due to this disparity, and the small 
number of microarray replications from which these genes were chosen, it cannot be 
concluded that treatment with rG3 is activating the GRB10, CDKN1B, or Caspase-9 
components of the PI3K/AKT pathway at the genetic level.
To check that the recombinant G3 protein used to treat the cells was functional, an 
MTT viability assay was performed in triplicate using varying concentrations of rG3. 
MDM-MB-231 cells were treated with 0, 4, 6, or 8 μg/ml of rG3 and incubated for 24 
hours. After the cells were lysed and OD readings were obtained, a stimulation index 
could be calculated. The data exhibit a dose-dependent inhibitory effect of rG3 on the 
cells, with 6 and 8 μg/ml causing a significant reduction in the viability of cells as 
compared to the control. This confirms the inhibitory effect of rG3 on cell growth and 
survival despite the inconsistent RT-PCR gene expression data and deems it necessary to 
investigate the PI3K/AKT pathway involved at a protein expression level.
Based on the activity of the PI3K/AKT pathway and its downstream constituents, 
the proteins chosen for study were AKT (phosphorylated and nonphosphorylated forms), 
IKKαβ, phosphorylated IKKβ, NFκB (phosphorylated and nonphosphorylated forms), 
and p53, with beta Actin as a control. As mentioned, AKT is a serine/threonine kinase 
with both regulatory and catalytic domains. PIP3 on the membrane associates with the PH 
domain of AKT and phosphorylates the molecule (Vivanco and Sawyers, 2002), allowing 
36
Akt to regulated cell cycle progression, survival, and cell migration through 
phosphorylation of the downstream IKKαβ complex. Furthermore, activation of the 
IKKαβ complex targets IκB proteins sequestering NFκB in the cytoplasm for degredation 
and NFκB is then free to regulate transcription in the nucleus, regulating both growth and 
apoptosis (Ryan et al., 2000). Lastly, p53 is negatively regulated by the p53-binding 
protein MDM2. When MDM2 is phosphorylated by AKT, it enhances p53 degredation 
and inhibits the pro-apoptotic effect of the p53 protein (Igor and Sawyers, 2002). These 
components of the PI3K/AKT signaling pathway are involved in regulating cell growth 
and in some cases, initiating apoptosis. This leads to the assumption that cell signaling 
and protein expression would be altered when MDM-231-MB breast cancer cells were 
treated with the recombinant G3 protein that has been shown to reduce cell viability 
through this pathway (Turner, 2008). Cells were treated with 40 μg of rG3 or 
corresponding media volume, incubated at 37ºC, collected, and lysed at 3, 6, 9, and 12 
hours after treatment.
Beta Actin protein levels are statistically the same in treated and untreated cells at 
0-12 hours. Any variation in the levels may be explained by the suggestion that with 
longer Western Blot incubation times, beta Actin antibodies seem less able to pick up any 
differences in different levels of its target protein in MDA-MB-231 breast cancer cells 
and that the protein is not always constantly expressed with time (Dittmer, 2006). It is 
important to note, however, that the relative density for beta Actin at all time points in all 
cells is clustered around 1 and is much more constant than any of the other protein 
densities, so it is suitable for a control for these research purposes. 
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The relative density of both AKT and phosphorylated AKT is significantly lower 
in cells treated with rG3 compared to untreated cells, suggesting that rG3 treatment is 
affecting not only the cell’s ability through PIP3 to phosphorylate and activate AKT but 
also degrading the the enzyme entirely.  The presence of both AKT and phosphorylated 
AKT increases with time in the untreated cells, which is due to an increase in survival 
and also likely to an increase in cell concentration with growth over time. In treated cells, 
the levels of AKT and phosphorylated AKT are lower after 12 hours of treatment when 
compared to 3 hours of treatment, showing a significant decrease in cell survival 
capability. These results coincide with current and numerous past studies that implicate 
activated AKT in regulation of cell cycle progression, promotion of survival, and 
increased cell migration (Schley et al., 2005; Vivanco and Sawyers, 2002). An active 
AKT has been detected in many cancers in vivo, including human breast cancer and 
unconstrained activation and expression of AKT has been shown to lead to the 
development of malignant tumors (Osaki et al., 2004). Recent studies also show 
phosphorylated AKT weakly expressed in normal breast tissue but abundant in invasive 
tumors (Crowell et al., 2007). Our results implicate less AKT activation and expression in 
cancer cells treated with rG3 and harmonize with the suggestion that inhibition of AKT 
and this pathway are possible therapeutic strategies for cancer (Osaki et al., 2004).
The next downstream protein of AKT investigated is the IKKαβ complex. When 
this classic IKK complex is phosphorylated by active AKT, the α and β subunits proceed 
to initiate NFκB transcription in the nucleus, promoting cell survival (Lee and Hung, 
2008). IKKβ and IKKα have both been recently shown to function as oncogenic kinases, 
so it is important to note the higher expression of both the IKKαβ complex and 
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phosphorylated IKKβ in untreated cancer cells compared to cells treated with rG3. 
Treatment significantly reduces the expression of IKKαβ in cells while untreated cells 
hold a relatively constant level of the kinase complex. Phosphorylated IKKβ is present in 
significantly lower levels in cells treated with rG3 and its expression increases with time 
in untreated cells, suggesting an oncogenic role of this protein in actively growing and 
unregulated cancer cells. A recent study implicates IKKβ as an oncoprotein in breast 
cancer because of its ability to degrade forkhead box O3a (FOXO3a) that normally is a 
transcription factor that promotes apoptosis. It is also known that the β subunit 
phosphorylates the inhibitory kinase of NFκB, allowing NFκB to translocate into the 
nucleus and promote the expression of genes involved in angiogenesis, invasion, 
metastasis, and cell survival. IKKα also may possibly serve as a promoter of tumor 
metastasis by down regulating tumor suppressors (Lee and Hung, 2008). Similar studies 
also report a role in apoptosis for IKKαβ and the IκB complex and show that IκB 
knockdown in breast cancer cells inhibits their proliferation and survival and significantly 
arrest the cells in the G0/G1 phase (Qin and Cheng, 2010). Our data also support this 
theory, as a reduction of IKKαβ and active IKKβ is seen in cells with lessened survival 
due to rG3 treatment. The relationship between the IKK complexes and NFκB and the 
inhibition seen by rG3 treatment suggest that the NFκB transcription factor will also be 
affected. 
The expression of the active form of NFκB, the transcription factor for cell 
survival and other processes activated by IKKαβ, is as expected for cells treated with 
rG3. Western Blots show a significantly higher expression of phosphorylated NFκB in 
untreated cells. The expression peaks at 6 hours, indicating the highest amount of 
39
transcription at this point, with a decrease at 12 hours but expression levels still above the 
control. For regular, inactive NFκB, higher levels are seen in the treated cells as 
compared to the untreated cells. This could be because the majority of NFκ B in 
untreated, actively proliferating cancer cells is in the active, phosphorylated form while 
activation is inhibited in the treated cells resulting from the low amount of active AKT 
and IKKαβ present with inhibition of the survival pathway by rG3. The NFκB family of 
transcription factors regulates expression genes involved in cell survival and proliferation 
and can also promote metastasis and angiogenesis (Gilmore et al., 2002). Inhibition of 
NFκB activity has been shown to reverse the malignant phenotype, and is of interest for 
therapeutics and intervention (Gilmore et al., 2002).Normally, the NFκB complex is 
tightly regulated and held in the cytoplasm through the IKK complex, but when liberated, 
can bind to target gene enhancers to promote an invasive capability of malignant tumor 
cells. There are many studies that show a variety of human tumor cell lines, including 
breast cancer cells, expressing constitutively nuclear and active NFκB activity (Gilmore 
et al., 2002). This supports the low levels of inactive NFκB seen in untreated breast 
cancer cells by suggesting most of it is in the phosphorylated form actively transcribing 
genes in the nucleus. 
Lastly, the largest trend in this research is seen in the expression of the tumor 
suppressor protein p53 in rG3 treated cancer cells. p53, in non-cancer cells, is continually 
produced and degraded immediately. The regulator of this protein, MDM2, is 
phosphorylated by AKT and can translocate into the nucleus, enhancing p53 degredation 
further (Igor and Sawyers, 2002). p53 mutations are the most common abnormality of 
human cancer and are seen in about 50% of all cancers, including breast cancer (Ziyaie et 
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al., 2000). It is also used as a diagnostic marker of breast cancer due to its prevalence in 
expression. Results of this study show very low levels of p53 expression in untreated, 
normally proliferating cancer cells. In treated cells, however, the levels of this protein are 
higher than the control cells and an extremely significant spike in p53 activity is observed 
beginning at only 9 hours after treatment. This increase in p53 activity suggests the cells 
are initiating apoptosis shortly after rG3 treatment. p53 induces apoptosis while AKT 
promotes cell survival, and previous studies have indicated cross-talk between AKT and 
p53 while influencing the apoptotic pathway in different ways (Wee and Aguda, 2006). A 
cell’s decision to live or die greatly depends on the levels of each protein, so treatment 
with rG3 is influencing this decision by decreasing levels of active AKT and significantly 
increasing p53 levels.
This study suggests there are significant differences in expression of PI3K/AKT 
proteins of the signal transduction cascade in MDA-MB-231 cells treated with the 
recombinant protein, rG3. This cascade has been implicated and investigated extensively 
for its role in tumor invasion and oncogenic metamorphosis, and is a target for inhibition 
of anti-cancer drugs (Chang et al., 2003). Inhibition of this pathway is important to 
control uncontrolled growth and invasion of malignant cells into tissues and is also easier 
than to restore function to abnormal tumor suppressor proteins. Thus, antiapoptotic 
signals from the PI3K/AKT pathway are a focus of current cancer drug therapy research. 
There are already AKT inhibitors that have been discovered, as well as PI3K inhibitors. It 
is more effective to target the whole pathway rather than just an upstream protein because 
for example, tumors growing with a mutation in a downstream component such as p53 
would not be inhibited by a drug solely targeting a single upstream protein (Hennessey, et 
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al., 2005). Most studies to date have been performed with inhibitory compounds that are 
virtually non-specific (Hennessey, et al., 2005), contrasting to the specificity and distinct 
binding properties of the recombinant G3 protein used in this study. Another benefit of 
the rG3 protein targeting integrin on the cell surface upstream of the entire PI3K/AKT 
pathway is that since this pathway does bifurcate and coalesce to such an extent, 
inhibition by rG3 is extremely global, and theoretically would be less vulnerable to the 
complexity of negative and positive feedback loops of the pathway. Therefore, the 
evidence presented here of rG3 treatment’s significant effect on the PI3K/AKT pathway, 
including AKT, IKKαβ, NFκB, and p53, implicates a role for this recombinant protein in 









beta Actin 5'-AATGTGGCCGAGGACTTTGATTGC-3' 5'-AGGATGGCAAGGGACTTCCTGTAA-3'
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Figure A2.  Standard curve for beta Actin housekeeping primer at .075 μg/ml and a 
temperature of 56ºC.
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Figure A3.  RT-PCR in triplicate with CDKN1B as the gene of interest was performed 
on RNA isolated from MDA-MB-231 breast cancer cells either treated with 175 µg/ml or 
none for control cells and collected 0, 12, 24, and hours after treatment. Fold change was 
calculated using Pfafl’s Equation. 
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Figure A4.  RT-PCR in triplicate with GRB10 as the gene of interest was performed on 
RNA isolated from MDA-MB-231 breast cancer cells either treated with 175 µg/ml or 
none for control cells and collected 0, 12, 24, and hours after treatment. Fold change was 
calculated using Pfafl’s Equation. 
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Figure A5.  RT-PCR in triplicate with Caspase-9 as the gene of interest was performed 
on RNA isolated from MDA-MB-231 breast cancer cells either treated with 175 µg/ml or 
none for control cells and collected 0, 12, 24, and hours after treatment. Fold change was 
calculated using Pfafl’s Equation. 
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Figure A6.  Western Immunoblot performed with a beta Actin (13E5) rabbit mAb at a 
1:1000 dilution. MDM-MB-231 breast cancer cells were treated with 175 μg/ml rG3 or 
media for control cells, and protein expression was observed at various hours after 
treatment.  Lane 10 represents the protein standard.  Lanes 1-9 are as follows: 12 hours 
treated, 9 hours treated, 6 hours treated, 3 hours treated, 12 hours untreated, 9 hours 
untreated, 6 hours untreated, 3 hours untreated, 0 hours untreated.
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Figure A7.  Western Immunoblot performed with am AKT rabbit mAb at a 1:1000 
dilution. MDM-MB-231 breast cancer cells were treated with 175 μg/ml rG3 or media for 
control cells, and protein expression was observed at various hours after treatment.  Lane 
10 represents the protein standard.  Lanes 1-9 are as follows: 12 hours treated, 9 hours 
treated, 6 hours treated, 3 hours treated, 12 hours untreated, 9 hours untreated, 6 hours 
untreated, 3 hours untreated, 0 hours untreated.
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Figure A8.  Western Immunoblot performed with a phospho-AKT rabbit mAb at a 
1:1000 dilution. MDM-MB-231 breast cancer cells were treated with 175 μg/ml rG3 or 
media for control cells, and protein expression was observed at various hours after 
treatment.  Lane 10 represents the protein standard.  Lanes 1-9 are as follows: 12 hours 
treated, 9 hours treated, 6 hours treated, 3 hours treated, 12 hours untreated, 9 hours 
untreated, 6 hours untreated, 3 hours untreated, 0 hours untreated.
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Figure A9.  Western Immunoblot performed with a p53 (7F5) rabbit mAb at a 1:1000 
dilution. MDM-MB-231 breast cancer cells were treated with 175 μg/ml rG3 or media for 
control cells, and protein expression was observed at various hours after treatment.  Lane 
6 represents the protein standard.  Lane 1-10 are as follows: 0 hours untreated, 3 hours 
untreated, 6 hours untreated, 9 hours untreated, 12 hours untreated, standard, 3 hours 
treated, 6 hours treated, 9 hours treated, 12 hours treated.
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Figure A10.  Western Immunoblot performed with a phospho-IKK-beta rabbit mAb at a 
1:1000 dilution. MDM-MB-231 breast cancer cells were treated with 175 μg/ml rG3 or 
media for control cells, and protein expression was observed at various hours after 
treatment.  Lane 5 represents the protein standard.  Lane 1-10 are as follows: 3 hours 
treated, 6 hours treated, 9 hours treated, 12 hours treated, marker, 0 hours untreated, 3 
hours untreated, 6 hours untreated, 9 hours untreated, 12 hours untreated.
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Figure A11.  Western Immunoblot performed with an IKK-alpha/beta (Ser176/180) 
rabbit mAb at a 1:1000 dilution. MDM-MB-231 breast cancer cells were treated with 175 
μg/ml rG3 or media for control cells, and protein expression was observed at various 
hours after treatment.  Lane 1 represents the protein standard.  Lane 2-10 are as follows: 0 
hours untreated, 3 hours untreated, 6 hours untreated, 9 hours untreated, 12 hours 
untreated, 3 hours treated, 6 hours treated, 9 hours treated, 12 hours treated.
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Figure A12.  Western Immunoblot performed with an NF-κB (p65) rabbit mAb at a 
1:2000 dilution. MDM-MB-231 breast cancer cells were treated with 175 μg/ml rG3 or 
media for control cells, and protein expression was observed at various hours after 
treatment.  Lane 7 represents the protein standard.  Lanes 1-10: 12 hours treated, 12 hours 
untreated, 9 hours treated, 9 hours untreated, 6 hours treated, 6 hours untreated, marker, 3 
hours treated, 3 hours untreated, 0 hours untreated.
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Figure A13.  Western Immunoblot performed with a phospho-NF-κB (p65) rabbit mAb 
at a 1:1000 dilution. MDM-MB-231 breast cancer cells were treated with 175 μg/ml rG3 
or media for control cells, and protein expression was observed at various hours after 
treatment.  Lane 1 represents the protein standard.  Lanes 2-10: 0 untreated, 3 untreated, 3 
treated, 6 untreated, 6 treated, 9 untreated, 9 treated, 12 untreated, 12 treated.
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